Multi-platform molecular profiling of pancreatic adenocarcinomas identifies BRCA1/2 mutations and PD-1/PD-L1 status with therapeutic implications


Sherri Z. Millis, Erin Baker, Ryan Bender, Jeff Swensen, Brian Abbott, Zoran Gatalica, MD, Sandeep Reddy, Alexander Rosemurgy, David Iannitti


Pancreas adenocarcinoma (PAC) is a challenging disease with overall single digit 5-year survivorship. BRCA1 and BRCA2 germline mutations are associated with increased risk of PC. Recent retrospective studies have described response of BRCA patients to platinum agents and PARP inhibitors. Additionally, immune therapies targeting the programmed cell death pathway in other cancers have shown promise; evaluating the incidence of aberrations of these markers in PAC impact therapeutic decisions.

Download Publication